NEWS-SaiAo Biotech | CAR-T Cell Therapy & Biopharmaceutical

EN

EN
عربي

Home / NEWS

Patient Success Stories

Literature Downloads

621ff475-90db-4fb2-9b37-bd820d867feb

01 January 2026

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

01 January 2026

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial

View More >>
05 April 2023

Long-term Follow-up of Donor-derived CD7 CAR T-cell Therapy in T-cell Acute Lymphoblastic Leukemia

J Hematol Oncol 2023: Long-term follow-up confirming durable remissions and manageable long-term safety of donor-derived CD7 CAR-T in T-ALL, supporting its role as a curative bridge to HSCT.

View More >>
03 February 2021

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Anti-BCMA CAR T-cell therapy is safe and effective for R/R multiple myeloma. For patients with high-risk factors, improvements to extend remission and more specific individualized therapies are needed

View More >>
04 May 2020

Pre-transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy followed by Haploidentical HSCT for Relapsed/Refractory Acute Lymphoblastic Leukemia

J Hematol Oncol 2020: Multi-center retrospective study establishing MRD-negativity pre-transplant as a key predictor of outcomes in the CAR-T + haploidentical HSCT sequence for r/r ALL.

View More >>
20 May 2019

CD22 CAR T-cell Therapy in Refractory or Relapsed B Acute Lymphoblastic Leukemia

Leukemia 2019: Clinical evaluation of CD22 CAR-T in r/r B-ALL, demonstrating activity in patients who relapsed after CD19-directed therapy and supporting CD22 as a viable alternative target.

View More >>

1 2 3 4 5